UNITED STATES
|
SECURITIES AND EXCHANGE COMMISSION
|
WASHINGTON, DC 20549
|
|
Large accelerated filer
x
|
Accelerated filer
o
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
o
|
|
|
Page
|
Item 1. Financial Statements
|
|
|
|
|
|
|
Index to unaudited consolidated financial statements filed as part of this report:
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Net revenues
|
$
|
1,925
|
|
|
$
|
1,902
|
|
|
$
|
3,764
|
|
|
$
|
3,648
|
|
|
|
|
|
|
|
|
|
||||||||
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of services
|
1,182
|
|
|
1,174
|
|
|
2,345
|
|
|
2,275
|
|
||||
Selling, general and administrative
|
429
|
|
|
440
|
|
|
848
|
|
|
855
|
|
||||
Amortization of intangible assets
|
20
|
|
|
25
|
|
|
41
|
|
|
47
|
|
||||
Other operating (income) expense, net
|
(7
|
)
|
|
1
|
|
|
1
|
|
|
1
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total operating costs and expenses
|
1,624
|
|
|
1,640
|
|
|
3,235
|
|
|
3,178
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating income
|
301
|
|
|
262
|
|
|
529
|
|
|
470
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense, net
|
(37
|
)
|
|
(42
|
)
|
|
(82
|
)
|
|
(81
|
)
|
||||
Equity in earnings of equity method investees
|
7
|
|
|
6
|
|
|
14
|
|
|
12
|
|
||||
Other (expense) income, net
|
(64
|
)
|
|
3
|
|
|
(142
|
)
|
|
4
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total non-operating expenses, net
|
(94
|
)
|
|
(33
|
)
|
|
(210
|
)
|
|
(65
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Income before income taxes
|
207
|
|
|
229
|
|
|
319
|
|
|
405
|
|
||||
Income tax expense
|
78
|
|
|
87
|
|
|
120
|
|
|
152
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net income
|
129
|
|
|
142
|
|
|
199
|
|
|
253
|
|
||||
Less: Net income attributable to noncontrolling interests
|
11
|
|
|
9
|
|
|
20
|
|
|
16
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net income attributable to Quest Diagnostics
|
$
|
118
|
|
|
$
|
133
|
|
|
$
|
179
|
|
|
$
|
237
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
||||||||
Earnings per share attributable to Quest Diagnostics’ common stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
$
|
0.82
|
|
|
$
|
0.92
|
|
|
$
|
1.24
|
|
|
$
|
1.64
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted
|
$
|
0.81
|
|
|
$
|
0.92
|
|
|
$
|
1.23
|
|
|
$
|
1.63
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
144
|
|
|
144
|
|
|
144
|
|
|
144
|
|
||||
Diluted
|
145
|
|
|
145
|
|
|
145
|
|
|
145
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Dividends per common share
|
$
|
0.38
|
|
|
$
|
0.33
|
|
|
$
|
0.76
|
|
|
$
|
0.66
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Net income
|
$
|
129
|
|
|
$
|
142
|
|
|
$
|
199
|
|
|
$
|
253
|
|
|
|
|
|
|
|
|
|
||||||||
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
||||||||
Currency translation
|
4
|
|
|
3
|
|
|
(2
|
)
|
|
2
|
|
||||
Market valuation, net of tax
|
—
|
|
|
3
|
|
|
2
|
|
|
3
|
|
||||
Net deferred loss on cash flow hedges, net of tax
|
1
|
|
|
(3
|
)
|
|
2
|
|
|
(5
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Other comprehensive income
|
5
|
|
|
3
|
|
|
2
|
|
|
—
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Comprehensive income
|
134
|
|
|
145
|
|
|
201
|
|
|
253
|
|
||||
Less: Comprehensive income attributable to noncontrolling interests
|
11
|
|
|
9
|
|
|
20
|
|
|
16
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Comprehensive income attributable to Quest Diagnostics
|
$
|
123
|
|
|
$
|
136
|
|
|
$
|
181
|
|
|
$
|
237
|
|
|
June 30,
2015 |
|
December 31,
2014 |
||||
Assets
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
150
|
|
|
$
|
192
|
|
Accounts receivable, net of allowance for doubtful accounts of $265 and $250 at June 30, 2015 and December 31, 2014, respectively
|
937
|
|
|
932
|
|
||
Inventories
|
109
|
|
|
110
|
|
||
Deferred income taxes
|
161
|
|
|
169
|
|
||
Prepaid expenses and other current assets
|
173
|
|
|
200
|
|
||
|
|
|
|
||||
Total current assets
|
1,530
|
|
|
1,603
|
|
||
Property, plant and equipment, net
|
906
|
|
|
933
|
|
||
Goodwill
|
5,987
|
|
|
6,032
|
|
||
Intangible assets, net
|
1,022
|
|
|
1,071
|
|
||
Other assets
|
219
|
|
|
218
|
|
||
Non-current assets held for sale
|
56
|
|
|
—
|
|
||
|
|
|
|
||||
Total assets
|
$
|
9,720
|
|
|
$
|
9,857
|
|
|
|
|
|
||||
Liabilities and Stockholders’ Equity
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable and accrued expenses
|
$
|
1,074
|
|
|
$
|
1,191
|
|
Current portion of long-term debt
|
168
|
|
|
518
|
|
||
|
|
|
|
||||
Total current liabilities
|
1,242
|
|
|
1,709
|
|
||
Long-term debt
|
3,568
|
|
|
3,224
|
|
||
Other liabilities
|
566
|
|
|
594
|
|
||
Stockholders’ equity:
|
|
|
|
|
|
||
Quest Diagnostics stockholders’ equity:
|
|
|
|
|
|
||
Common stock, par value $0.01 per share; 600 shares authorized at both June 30, 2015 and December 31, 2014; 216 shares and 215 shares issued at June 30, 2015 and December 31, 2014, respectively
|
2
|
|
|
2
|
|
||
Additional paid-in capital
|
2,444
|
|
|
2,418
|
|
||
Retained earnings
|
5,793
|
|
|
5,723
|
|
||
Accumulated other comprehensive loss
|
(25
|
)
|
|
(27
|
)
|
||
Treasury stock, at cost; 72 shares and 71 shares at June 30, 2015 and December 31, 2014, respectively
|
(3,900
|
)
|
|
(3,815
|
)
|
||
|
|
|
|
||||
Total Quest Diagnostics stockholders’ equity
|
4,314
|
|
|
4,301
|
|
||
Noncontrolling interests
|
30
|
|
|
29
|
|
||
|
|
|
|
||||
Total stockholders’ equity
|
4,344
|
|
|
4,330
|
|
||
|
|
|
|
||||
Total liabilities and stockholders’ equity
|
$
|
9,720
|
|
|
$
|
9,857
|
|
|
Six Months Ended June 30,
|
||||||
|
2015
|
|
2014
|
||||
Cash flows from operating activities:
|
|
|
|
|
|
||
Net income
|
$
|
199
|
|
|
$
|
253
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||
Depreciation and amortization
|
153
|
|
|
156
|
|
||
Provision for doubtful accounts
|
158
|
|
|
148
|
|
||
Deferred income tax benefit
|
(5
|
)
|
|
(26
|
)
|
||
Stock-based compensation expense
|
27
|
|
|
25
|
|
||
Excess tax benefits from stock-based compensation arrangements
|
(3
|
)
|
|
—
|
|
||
Other, net
|
(5
|
)
|
|
(2
|
)
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||
Accounts receivable
|
(163
|
)
|
|
(191
|
)
|
||
Accounts payable and accrued expenses
|
(49
|
)
|
|
(39
|
)
|
||
Income taxes payable
|
17
|
|
|
44
|
|
||
Other assets and liabilities, net
|
(2
|
)
|
|
(4
|
)
|
||
|
|
|
|
||||
Net cash provided by operating activities
|
327
|
|
|
364
|
|
||
|
|
|
|
||||
Cash flows from investing activities:
|
|
|
|
|
|
||
Business acquisitions, net of cash acquired
|
(6
|
)
|
|
(723
|
)
|
||
Capital expenditures
|
(117
|
)
|
|
(117
|
)
|
||
Increase in investments and other assets
|
—
|
|
|
(1
|
)
|
||
|
|
|
|
||||
Net cash used in investing activities
|
(123
|
)
|
|
(841
|
)
|
||
|
|
|
|
||||
Cash flows from financing activities:
|
|
|
|
|
|
||
Proceeds from borrowings
|
1,829
|
|
|
1,738
|
|
||
Repayments of debt
|
(1,821
|
)
|
|
(1,159
|
)
|
||
Purchases of treasury stock
|
(149
|
)
|
|
(57
|
)
|
||
Exercise of stock options
|
55
|
|
|
30
|
|
||
Excess tax benefits from stock-based compensation arrangements
|
3
|
|
|
—
|
|
||
Dividends paid
|
(103
|
)
|
|
(91
|
)
|
||
Distributions to noncontrolling interests
|
(19
|
)
|
|
(14
|
)
|
||
Other financing activities, net
|
(41
|
)
|
|
(13
|
)
|
||
|
|
|
|
||||
Net cash (used in) provided by financing activities
|
(246
|
)
|
|
434
|
|
||
|
|
|
|
||||
Net change in cash and cash equivalents
|
(42
|
)
|
|
(43
|
)
|
||
Cash and cash equivalents, beginning of period
|
192
|
|
|
187
|
|
||
|
|
|
|
||||
Cash and cash equivalents, end of period
|
$
|
150
|
|
|
$
|
144
|
|
|
|
|
Quest Diagnostics Stockholders’ Equity
|
|
|
|
|
|||||||||||||||||||||||
|
Shares of
Common Stock Outstanding |
|
Common
Stock
|
|
Additional
Paid-In
Capital
|
|
Retained
Earnings
|
|
Accumulated
Other
Compre-
hensive Loss
|
|
Treasury
Stock, at
Cost
|
|
Non-
controlling
Interests
|
|
Total Stock-
holders’
Equity
|
|||||||||||||||
Balance, December 31, 2014
|
144
|
|
|
$
|
2
|
|
|
$
|
2,418
|
|
|
$
|
5,723
|
|
|
$
|
(27
|
)
|
|
$
|
(3,815
|
)
|
|
$
|
29
|
|
|
$
|
4,330
|
|
Net income
|
|
|
|
|
|
|
|
|
|
179
|
|
|
|
|
|
|
|
|
20
|
|
|
199
|
|
|||||||
Other comprehensive income, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
2
|
|
|||||||
Dividends declared
|
|
|
|
|
|
|
|
|
|
(109
|
)
|
|
|
|
|
|
|
|
|
|
|
(109
|
)
|
|||||||
Distributions to noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(19
|
)
|
|
(19
|
)
|
|||||||
Issuance of common stock under benefit plans
|
1
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
|
7
|
|
|
|
|
|
11
|
|
|||||||
Stock-based compensation expense
|
|
|
|
|
|
|
25
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
27
|
|
|||||||
Exercise of stock options
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
55
|
|
|
|
|
|
55
|
|
|||||||
Shares to cover employee payroll tax withholdings on stock issued under benefit plans
|
|
|
|
|
|
|
(6
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6
|
)
|
|||||||
Tax benefits associated with stock-based compensation plans
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
|||||||
Purchases of treasury stock
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(149
|
)
|
|
|
|
|
(149
|
)
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, June 30, 2015
|
144
|
|
|
$
|
2
|
|
|
$
|
2,444
|
|
|
$
|
5,793
|
|
|
$
|
(25
|
)
|
|
$
|
(3,900
|
)
|
|
$
|
30
|
|
|
$
|
4,344
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
|
|
Quest Diagnostics Stockholders’ Equity
|
|
|
|
|
||||||||||||||||||||||
|
Shares of
Common
Stock
Outstanding
|
|
Common
Stock
|
|
Additional
Paid-In
Capital
|
|
Retained
Earnings
|
|
Accumulated
Other
Compre-
hensive Loss
|
|
Treasury
Stock, at
Cost
|
|
Non-
controlling
Interests
|
|
Total Stock-
holders’
Equity
|
|||||||||||||||
Balance, December 31, 2013
|
144
|
|
|
$
|
2
|
|
|
$
|
2,379
|
|
|
$
|
5,358
|
|
|
$
|
(8
|
)
|
|
$
|
(3,783
|
)
|
|
$
|
25
|
|
|
$
|
3,973
|
|
Net income
|
|
|
|
|
|
|
|
|
|
237
|
|
|
|
|
|
|
|
|
16
|
|
|
253
|
|
|||||||
Other comprehensive income, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
—
|
|
|
|
|
|
|
|
|
—
|
|
|||||||
Dividends declared
|
|
|
|
|
|
|
|
|
|
(95
|
)
|
|
|
|
|
|
|
|
|
|
|
(95
|
)
|
|||||||
Distributions to noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(14
|
)
|
|
(14
|
)
|
|||||||
Issuance of common stock under benefit plans
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9
|
|
|
|
|
|
9
|
|
|||||||
Stock-based compensation expense
|
|
|
|
|
|
|
23
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
25
|
|
|||||||
Exercise of stock options
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
33
|
|
|
|
|
|
30
|
|
|||||||
Shares to cover employee payroll tax withholdings on stock issued under benefit plans
|
|
|
|
|
|
|
(5
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5
|
)
|
|||||||
Purchases of treasury stock
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(57
|
)
|
|
|
|
|
(57
|
)
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, June 30, 2014
|
144
|
|
|
$
|
2
|
|
|
$
|
2,394
|
|
|
$
|
5,500
|
|
|
$
|
(8
|
)
|
|
$
|
(3,796
|
)
|
|
$
|
27
|
|
|
$
|
4,119
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Amounts attributable to Quest Diagnostics’ stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income attributable to Quest Diagnostics
|
$
|
118
|
|
|
$
|
133
|
|
|
$
|
179
|
|
|
$
|
237
|
|
Less: Earnings allocated to participating securities
|
1
|
|
|
—
|
|
|
1
|
|
|
1
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
|
$
|
117
|
|
|
$
|
133
|
|
|
$
|
178
|
|
|
$
|
236
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding – basic
|
144
|
|
|
144
|
|
|
144
|
|
|
144
|
|
||||
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Stock options and performance share units
|
1
|
|
|
1
|
|
|
1
|
|
|
1
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding – diluted
|
145
|
|
|
145
|
|
|
145
|
|
|
145
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Earnings per share attributable to Quest Diagnostics’ common stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic
|
$
|
0.82
|
|
|
$
|
0.92
|
|
|
$
|
1.24
|
|
|
$
|
1.64
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted
|
$
|
0.81
|
|
|
$
|
0.92
|
|
|
$
|
1.23
|
|
|
$
|
1.63
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||
Stock options and performance share units
|
2
|
|
|
3
|
|
|
2
|
|
|
4
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Employee separation costs
|
$
|
6
|
|
|
$
|
6
|
|
|
$
|
21
|
|
|
$
|
14
|
|
Facility-related costs
|
—
|
|
|
3
|
|
|
—
|
|
|
4
|
|
||||
Asset impairment charges
|
—
|
|
|
1
|
|
|
—
|
|
|
1
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total restructuring charges
|
$
|
6
|
|
|
$
|
10
|
|
|
$
|
21
|
|
|
$
|
19
|
|
|
Employee Separation Costs
|
|
Facility-Related Costs
|
|
Total
|
||||||
|
|
|
|
|
|
||||||
Balance, December 31, 2014
|
$
|
18
|
|
|
$
|
11
|
|
|
$
|
29
|
|
Current period charges
|
21
|
|
|
—
|
|
|
21
|
|
|||
Less:
|
|
|
|
|
|
||||||
Cash payments
|
(19
|
)
|
|
(3
|
)
|
|
(22
|
)
|
|||
Other / adjustments
|
—
|
|
|
(3
|
)
|
|
(3
|
)
|
|||
|
|
|
|
|
|
||||||
Balance, June 30, 2015
|
$
|
20
|
|
|
$
|
5
|
|
|
$
|
25
|
|
|
|
|
Basis of Fair Value Measurements
|
||||||||||||
|
|
|
Quoted
Prices in
Active
Markets for
Identical
Assets /
Liabilities
|
|
Significant
Other
Observable
Inputs
|
|
Significant
Unobservable
Inputs
|
||||||||
June 30, 2015
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Trading securities
|
$
|
48
|
|
|
$
|
48
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Cash surrender value of life insurance policies
|
30
|
|
|
—
|
|
|
30
|
|
|
—
|
|
||||
Interest rate swaps
|
15
|
|
|
—
|
|
|
15
|
|
|
—
|
|
||||
Available-for-sale equity securities
|
10
|
|
|
10
|
|
|
—
|
|
|
—
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total
|
$
|
103
|
|
|
$
|
58
|
|
|
$
|
45
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Deferred compensation liabilities
|
$
|
84
|
|
|
$
|
—
|
|
|
$
|
84
|
|
|
$
|
—
|
|
Interest rate swaps
|
12
|
|
|
—
|
|
|
12
|
|
|
—
|
|
||||
Call option
|
4
|
|
|
—
|
|
|
—
|
|
|
4
|
|
||||
Contingent consideration
|
3
|
|
|
—
|
|
|
—
|
|
|
3
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total
|
$
|
103
|
|
|
$
|
—
|
|
|
$
|
96
|
|
|
$
|
7
|
|
|
|
|
Basis of Fair Value Measurements
|
||||||||||||
|
|
|
Quoted
Prices in
Active
Markets for
Identical
Assets /
Liabilities
|
|
Significant
Other
Observable
Inputs
|
|
Significant
Unobservable
Inputs
|
||||||||
December 31, 2014
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Trading securities
|
$
|
49
|
|
|
$
|
49
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Cash surrender value of life insurance policies
|
30
|
|
|
—
|
|
|
30
|
|
|
—
|
|
||||
Interest rate swaps
|
17
|
|
|
—
|
|
|
17
|
|
|
—
|
|
||||
Available-for-sale equity securities
|
9
|
|
|
9
|
|
|
—
|
|
|
—
|
|
||||
Put option
|
1
|
|
|
—
|
|
|
—
|
|
|
1
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total
|
$
|
106
|
|
|
$
|
58
|
|
|
$
|
47
|
|
|
$
|
1
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Deferred compensation liabilities
|
$
|
85
|
|
|
$
|
—
|
|
|
$
|
85
|
|
|
$
|
—
|
|
Contingent consideration
|
17
|
|
|
—
|
|
|
—
|
|
|
17
|
|
||||
Forward starting interest rate swaps
|
15
|
|
|
—
|
|
|
15
|
|
|
—
|
|
||||
Interest rate swaps
|
13
|
|
|
—
|
|
|
13
|
|
|
—
|
|
||||
Call option
|
5
|
|
|
—
|
|
|
—
|
|
|
5
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total
|
$
|
135
|
|
|
$
|
—
|
|
|
$
|
113
|
|
|
$
|
22
|
|
|
Assets
|
|
Liabilities
|
||||||||||||
|
Put Option Derivative Asset
|
|
Contingent Consideration
|
|
Call Option Derivative Liability
|
|
Total Liabilities
|
||||||||
|
|
|
|
|
|
|
|
||||||||
Balance, December 31, 2014
|
1
|
|
|
$
|
17
|
|
|
5
|
|
|
$
|
22
|
|
||
Settlements
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
||||
Total gains/losses - realized/unrealized:
|
|
|
|
|
|
|
|
||||||||
Included in earnings
|
(1
|
)
|
|
(13
|
)
|
|
(1
|
)
|
|
(14
|
)
|
||||
Balance, June 30, 2015
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
4
|
|
|
$
|
7
|
|
|
June 30,
2015 |
|
December 31,
2014 |
||||
Balance, beginning of period
|
$
|
6,032
|
|
|
$
|
5,649
|
|
Goodwill acquired during the period
|
2
|
|
|
383
|
|
||
Reclassification to assets held for sale
|
(47
|
)
|
|
—
|
|
||
Balance, end of period
|
$
|
5,987
|
|
|
$
|
6,032
|
|
|
Weighted
Average
Amortization
Period
(in years)
|
|
June 30, 2015
|
|
December 31, 2014
|
||||||||||||||||||||
|
|
|
Cost
|
|
Accumulated
Amortization
|
|
Net
|
|
Cost
|
|
Accumulated
Amortization
|
|
Net
|
||||||||||||
Amortizing intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Customer-related intangibles
|
19
|
|
$
|
923
|
|
|
$
|
(278
|
)
|
|
$
|
645
|
|
|
$
|
929
|
|
|
$
|
(259
|
)
|
|
$
|
670
|
|
Non-compete agreements
|
5
|
|
6
|
|
|
(3
|
)
|
|
3
|
|
|
43
|
|
|
(37
|
)
|
|
6
|
|
||||||
Technology
|
14
|
|
117
|
|
|
(43
|
)
|
|
74
|
|
|
118
|
|
|
(38
|
)
|
|
80
|
|
||||||
Other
|
8
|
|
119
|
|
|
(64
|
)
|
|
55
|
|
|
152
|
|
|
(82
|
)
|
|
70
|
|
||||||
Total
|
17
|
|
1,165
|
|
|
(388
|
)
|
|
777
|
|
|
1,242
|
|
|
(416
|
)
|
|
826
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Intangible assets not subject to amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Trade names
|
|
|
244
|
|
|
—
|
|
|
244
|
|
|
244
|
|
|
—
|
|
|
244
|
|
||||||
Other
|
|
|
1
|
|
|
—
|
|
|
1
|
|
|
1
|
|
|
—
|
|
|
1
|
|
||||||
Total intangible assets
|
|
$
|
1,410
|
|
|
$
|
(388
|
)
|
|
$
|
1,022
|
|
|
$
|
1,487
|
|
|
$
|
(416
|
)
|
|
$
|
1,071
|
|
|
June 30,
2015 |
|
December 31,
2014 |
||||
|
|
|
|
||||
Secured Receivables Credit Facility (0.88% at June 30, 2015)
|
$
|
85
|
|
|
$
|
—
|
|
5.45% Senior Notes due November 2015
|
—
|
|
|
500
|
|
||
3.20% Senior Notes due April 2016
|
151
|
|
|
304
|
|
||
6.40% Senior Notes due July 2017
|
—
|
|
|
375
|
|
||
2.70% Senior Notes due April 2019
|
300
|
|
|
300
|
|
||
4.75% Senior Notes due January 2020
|
523
|
|
|
524
|
|
||
2.50% Senior Notes due March 2020
|
299
|
|
|
—
|
|
||
4.70% Senior Notes due April 2021
|
550
|
|
|
549
|
|
||
4.25% Senior Notes due April 2024
|
309
|
|
|
311
|
|
||
3.50% Senior Notes due March 2025
|
597
|
|
|
—
|
|
||
6.95% Senior Notes due July 2037
|
247
|
|
|
421
|
|
||
5.75% Senior Notes due January 2040
|
368
|
|
|
439
|
|
||
4.70% Senior Notes due March 2045
|
300
|
|
|
—
|
|
||
Other
|
34
|
|
|
39
|
|
||
Debt issuance costs
|
(27
|
)
|
|
(20
|
)
|
||
|
|
|
|
||||
Total long-term debt
|
3,736
|
|
|
3,742
|
|
||
Less: Current portion of long-term debt
|
168
|
|
|
518
|
|
||
|
|
|
|
||||
Total long-term debt, net of current portion
|
$
|
3,568
|
|
|
$
|
3,224
|
|
Year Ending December 31,
|
|
||
Remainder of 2015
|
$
|
12
|
|
2016
|
244
|
|
|
2017
|
6
|
|
|
2018
|
4
|
|
|
2019
|
302
|
|
|
2020
|
801
|
|
|
Thereafter
|
2,375
|
|
|
|
|
||
Total maturities of long-term debt
|
3,744
|
|
|
Unamortized discount
|
(17
|
)
|
|
Debt issuance costs
|
(27
|
)
|
|
Fair value basis adjustments attributable to hedged debt
|
36
|
|
|
|
|
||
Total long-term debt
|
3,736
|
|
|
Less: Current portion of long-term debt
|
168
|
|
|
|
|
||
Total long-term debt, net of current portion
|
$
|
3,568
|
|
|
|
|
|
Notional Amount
|
||||||
Debt Instrument
|
|
Floating Rate Paid by the Company
|
|
June 30, 2015
|
|
December 31, 2014
|
||||
|
|
|
|
|
|
|
||||
3.20% Senior Notes due April 2016
|
|
Six-month LIBOR plus a 2.3% spread
|
|
$
|
—
|
|
|
$
|
200
|
|
4.75% Senior Notes due January 2020
|
|
One-month LIBOR plus a 3.6% spread
|
|
350
|
|
|
350
|
|
||
4.70% Senior Notes due April 2021
|
|
One-month LIBOR plus a 2.45% to 3.39% spread
|
|
400
|
|
|
400
|
|
||
4.25% Senior Notes due April 2024
|
|
One-month LIBOR plus a 1.54% to 1.59% spread
|
|
250
|
|
|
250
|
|
||
3.50% Senior Notes due March 2025
|
|
One-month LIBOR plus a 1.44% spread
|
|
200
|
|
|
—
|
|
||
|
|
|
|
|
|
|
||||
|
|
|
|
$
|
1,200
|
|
|
$
|
1,200
|
|
|
June 30, 2015
|
|
December 31, 2014
|
||||||||
|
Balance Sheet
Classification
|
|
Fair Value
|
|
Balance Sheet
Classification
|
|
Fair Value
|
||||
Derivatives Designated as Hedging Instruments
|
|
|
|
|
|
|
|
|
|
||
Asset Derivatives:
|
|
|
|
|
|
|
|
|
|
||
Interest rate swaps
|
Other assets
|
|
$
|
15
|
|
|
Other assets
|
|
$
|
17
|
|
|
|
|
|
|
|
|
|
||||
Liability Derivatives:
|
|
|
|
|
|
|
|
||||
Interest rate swaps
|
Other liabilities
|
|
12
|
|
|
Other liabilities
|
|
13
|
|
||
Forward starting interest rate swaps
|
|
|
—
|
|
|
Other liabilities
|
|
15
|
|
||
Total Liability Derivatives
|
|
|
12
|
|
|
|
|
28
|
|
||
|
|
|
|
|
|
|
|
||||
Derivatives Not Designated as Hedging Instruments
|
|
|
|
|
|
|
|
|
|
||
Asset Derivatives:
|
|
|
|
|
|
|
|
|
|
||
Put option
|
|
|
—
|
|
|
Prepaid expenses and other current assets
|
|
1
|
|
||
|
|
|
|
|
|
|
|
||||
Liability Derivatives:
|
|
|
|
|
|
|
|
||||
Call option
|
Accounts payable and accrued expenses
|
|
4
|
|
|
Accounts payable and accrued expenses
|
|
5
|
|
||
|
|
|
|
|
|
|
|
||||
Total Net Derivatives (Liabilities)
|
|
|
$
|
(1
|
)
|
|
|
|
$
|
(15
|
)
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Depreciation expense
|
$
|
55
|
|
|
$
|
56
|
|
|
$
|
112
|
|
|
$
|
109
|
|
Amortization expense
|
20
|
|
|
25
|
|
|
41
|
|
|
47
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Depreciation and amortization expense
|
$
|
75
|
|
|
$
|
81
|
|
|
$
|
153
|
|
|
$
|
156
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense
|
$
|
(37
|
)
|
|
$
|
(42
|
)
|
|
$
|
(83
|
)
|
|
$
|
(82
|
)
|
Interest income
|
—
|
|
|
—
|
|
|
1
|
|
|
1
|
|
||||
|
|
|
|
|
|
|
|
|
|||||||
Interest expense, net
|
$
|
(37
|
)
|
|
$
|
(42
|
)
|
|
$
|
(82
|
)
|
|
$
|
(81
|
)
|
|
|
|
|
|
|
|
|
||||||||
Interest paid
|
$
|
45
|
|
|
$
|
30
|
|
|
$
|
99
|
|
|
$
|
82
|
|
Income taxes paid
|
90
|
|
|
129
|
|
|
109
|
|
|
138
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Assets acquired under capital leases
|
2
|
|
|
8
|
|
|
2
|
|
|
10
|
|
||||
Accounts payable associated with capital expenditures
|
9
|
|
|
14
|
|
|
9
|
|
|
14
|
|
||||
Dividends payable
|
$
|
55
|
|
|
$
|
48
|
|
|
$
|
55
|
|
|
$
|
48
|
|
|
|
|
|
|
|
|
|
||||||||
Businesses acquired:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Fair value of assets acquired
|
$
|
2
|
|
|
$
|
199
|
|
|
$
|
2
|
|
|
$
|
845
|
|
Fair value of liabilities assumed
|
—
|
|
|
12
|
|
|
—
|
|
|
82
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Fair value of net assets acquired
|
2
|
|
|
187
|
|
|
2
|
|
|
763
|
|
||||
Merger consideration paid (payable), net
|
4
|
|
|
(30
|
)
|
|
4
|
|
|
(30
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Cash paid for business acquisitions
|
6
|
|
|
157
|
|
|
6
|
|
|
733
|
|
||||
Less: Cash acquired
|
—
|
|
|
1
|
|
|
—
|
|
|
10
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Business acquisitions, net of cash acquired
|
$
|
6
|
|
|
$
|
156
|
|
|
$
|
6
|
|
|
$
|
723
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Net revenues:
|
|
|
|
|
|
|
|
|
|
|
|
||||
DIS business
|
$
|
1,771
|
|
|
$
|
1,763
|
|
|
$
|
3,463
|
|
|
$
|
3,377
|
|
All other operating segments
|
154
|
|
|
139
|
|
|
301
|
|
|
271
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total net revenues
|
$
|
1,925
|
|
|
$
|
1,902
|
|
|
$
|
3,764
|
|
|
$
|
3,648
|
|
|
|
|
|
|
|
|
|
||||||||
Operating earnings (loss):
|
|
|
|
|
|
|
|
|
|
|
|
||||
DIS business
|
$
|
302
|
|
|
$
|
293
|
|
|
$
|
544
|
|
|
$
|
524
|
|
All other operating segments
|
30
|
|
|
22
|
|
|
56
|
|
|
40
|
|
||||
General corporate activities
|
(31
|
)
|
|
(53
|
)
|
|
(71
|
)
|
|
(94
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Total operating income
|
301
|
|
|
262
|
|
|
529
|
|
|
470
|
|
||||
Non-operating expenses, net
|
(94
|
)
|
|
(33
|
)
|
|
(210
|
)
|
|
(65
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Income before income taxes
|
207
|
|
|
229
|
|
|
319
|
|
|
405
|
|
||||
Income tax expense
|
78
|
|
|
87
|
|
|
120
|
|
|
152
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net income
|
129
|
|
|
142
|
|
|
199
|
|
|
253
|
|
||||
Less: Net income attributable to noncontrolling interests
|
11
|
|
|
9
|
|
|
20
|
|
|
16
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net income attributable to Quest Diagnostics
|
$
|
118
|
|
|
$
|
133
|
|
|
$
|
179
|
|
|
$
|
237
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
•
|
We grew total net revenues
1.2%
to
$1.9 billion
and operating income
14.9%
to
$301 million
.
|
•
|
We continue to grow revenues from new relationships with hospitals and integrated delivery networks by helping them improve health outcomes and reduce costs. Most recently, we entered into a definitive agreement to acquire MemorialCare Health System's laboratory outreach services business, which provides outreach laboratory testing in southern California. The acquisition is expected to close in August 2015.
|
•
|
We are enhancing our diagnostic information services to help customers with population health, data analytics and decision support tools which will help to drive growth as well as deliver a superior customer experience.
|
•
|
We closed on our Q
2
Solutions joint venture with Quintiles Transnational Holdings Inc. ("Quintiles") on July 1, 2015, forming a global clinical trials central laboratory services company into which we contributed our clinical trials testing business in exchange for a 40% ownership interest.
|
•
|
We completed the refinancing of over $1.2 billion in outstanding senior notes, resulting in reduced future interest expense and an improved maturity profile.
|
•
|
We repurchased
$39 million
of our common stock as part of our Common Stock repurchase program.
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||||||||||||||||
|
2015
|
|
2014
|
|
Increase
(Decrease) |
|
% Increase
(Decrease) |
|
2015
|
|
2014
|
|
Increase
(Decrease) |
|
% Increase
(Decrease) |
||||||||||||||
|
(dollars in millions, except per share amounts)
|
||||||||||||||||||||||||||||
Net revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
DIS business
|
$
|
1,771
|
|
|
$
|
1,763
|
|
|
$
|
8
|
|
|
0.4
|
%
|
|
$
|
3,463
|
|
|
$
|
3,377
|
|
|
$
|
86
|
|
|
2.6
|
%
|
DS businesses
|
154
|
|
|
139
|
|
|
15
|
|
|
11.1
|
|
|
301
|
|
|
271
|
|
|
30
|
|
|
11.1
|
|
||||||
Total net revenues
|
$
|
1,925
|
|
|
$
|
1,902
|
|
|
$
|
23
|
|
|
1.2
|
%
|
|
$
|
3,764
|
|
|
$
|
3,648
|
|
|
$
|
116
|
|
|
3.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cost of services
|
$
|
1,182
|
|
|
$
|
1,174
|
|
|
$
|
8
|
|
|
0.7
|
%
|
|
$
|
2,345
|
|
|
$
|
2,275
|
|
|
$
|
70
|
|
|
3.1
|
%
|
Selling, general and administrative
|
429
|
|
|
440
|
|
|
(11
|
)
|
|
(2.7
|
)
|
|
848
|
|
|
855
|
|
|
(7
|
)
|
|
(0.9
|
)
|
||||||
Amortization of intangible assets
|
20
|
|
|
25
|
|
|
(5
|
)
|
|
(20.5
|
)
|
|
41
|
|
|
47
|
|
|
(6
|
)
|
|
(12.1
|
)
|
||||||
Other operating (income) expense, net
|
(7
|
)
|
|
1
|
|
|
(8
|
)
|
|
NM
|
|
|
1
|
|
|
1
|
|
|
—
|
|
|
NM
|
|
||||||
Total operating costs and expenses
|
$
|
1,624
|
|
|
$
|
1,640
|
|
|
$
|
(16
|
)
|
|
(1.0
|
)%
|
|
$
|
3,235
|
|
|
$
|
3,178
|
|
|
$
|
57
|
|
|
1.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Operating income
|
$
|
301
|
|
|
$
|
262
|
|
|
$
|
39
|
|
|
14.9
|
%
|
|
$
|
529
|
|
|
$
|
470
|
|
|
$
|
59
|
|
|
12.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Interest expense, net
|
$
|
(37
|
)
|
|
$
|
(42
|
)
|
|
$
|
(5
|
)
|
|
(9.8
|
)%
|
|
$
|
(82
|
)
|
|
$
|
(81
|
)
|
|
$
|
1
|
|
|
2.1
|
%
|
Equity in earnings of equity method investees
|
7
|
|
|
6
|
|
|
1
|
|
|
1.9
|
|
|
14
|
|
|
12
|
|
|
2
|
|
|
10.2
|
|
||||||
Other (expense) income, net
|
(64
|
)
|
|
3
|
|
|
67
|
|
|
NM
|
|
|
(142
|
)
|
|
4
|
|
|
146
|
|
|
NM
|
|
||||||
Total non-operating expenses, net
|
$
|
(94
|
)
|
|
$
|
(33
|
)
|
|
$
|
61
|
|
|
NM
|
|
|
$
|
(210
|
)
|
|
$
|
(65
|
)
|
|
$
|
145
|
|
|
NM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Income tax expense
|
$
|
78
|
|
|
$
|
87
|
|
|
$
|
(9
|
)
|
|
(10.8
|
)%
|
|
$
|
120
|
|
|
$
|
152
|
|
|
$
|
(32
|
)
|
|
(21.3
|
)%
|
Effective income tax rate
|
37.6
|
%
|
|
37.9
|
%
|
|
(0.3
|
)%
|
|
NM
|
|
|
37.5
|
%
|
|
37.5
|
%
|
|
—
|
%
|
|
NM
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Net income attributable to Quest Diagnostics
|
$
|
118
|
|
|
$
|
133
|
|
|
$
|
(15
|
)
|
|
(11.5
|
)%
|
|
$
|
179
|
|
|
$
|
237
|
|
|
$
|
(58
|
)
|
|
(24.5
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Diluted earnings per common share attributable to Quest Diagnostics’ common stockholders
|
$
|
0.81
|
|
|
$
|
0.92
|
|
|
$
|
(0.11
|
)
|
|
(12.0
|
)%
|
|
$
|
1.23
|
|
|
$
|
1.63
|
|
|
$
|
(0.40
|
)
|
|
(24.5
|
)%
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||
|
|
|
|
|
|
|
|
||||
Net revenues:
|
|
|
|
|
|
|
|
||||
DIS business
|
92.0
|
%
|
|
92.7
|
%
|
|
92.0
|
%
|
|
92.6
|
%
|
DS businesses
|
8.0
|
|
|
7.3
|
|
|
8.0
|
|
|
7.4
|
|
Total net revenues
|
100.0
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
||||
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
||
Cost of services
|
61.4
|
%
|
|
61.7
|
%
|
|
62.3
|
%
|
|
62.4
|
%
|
Selling, general and administrative
|
22.3
|
|
|
23.1
|
|
|
22.5
|
|
|
23.4
|
|
Amortization of intangible assets
|
1.0
|
|
|
1.3
|
|
|
1.1
|
|
|
1.3
|
|
Other operating (income) expense, net
|
(0.3
|
)
|
|
0.1
|
|
|
—
|
|
|
—
|
|
Total operating costs and expenses
|
84.4
|
%
|
|
86.2
|
%
|
|
85.9
|
%
|
|
87.1
|
%
|
|
|
|
|
|
|
|
|
||||
Operating income
|
15.6
|
%
|
|
13.8
|
%
|
|
14.1
|
%
|
|
12.9
|
%
|
|
|
|
|
|
|
|
|
||||
Bad debt expense
|
4.1
|
%
|
|
3.9
|
%
|
|
4.2
|
%
|
|
4.1
|
%
|
|
Six Months Ended June 30,
|
||||||
|
2015
|
|
2014
|
||||
|
(dollars in millions)
|
||||||
Net cash provided by operating activities
|
$
|
327
|
|
|
$
|
364
|
|
Net cash used in investing activities
|
(123
|
)
|
|
(841
|
)
|
||
Net cash (used in) provided by financing activities
|
(246
|
)
|
|
434
|
|
||
|
|
|
|
||||
Net change in cash and cash equivalents
|
$
|
(42
|
)
|
|
$
|
(43
|
)
|
|
|
Payments due by period
|
||||||||||||||||||
|
|
(in millions)
|
||||||||||||||||||
Contractual Obligations
|
|
Total
|
|
Remainder of 2015
|
|
1-3 years
|
|
3-5 years
|
|
After 5 years
|
||||||||||
Outstanding debt
|
|
$
|
3,716
|
|
|
$
|
6
|
|
|
$
|
235
|
|
|
$
|
300
|
|
|
$
|
3,175
|
|
Capital lease obligations
|
|
28
|
|
|
6
|
|
|
15
|
|
|
6
|
|
|
1
|
|
|||||
Interest payments on outstanding debt
|
|
1,879
|
|
|
71
|
|
|
267
|
|
|
260
|
|
|
1,281
|
|
|||||
Operating leases
|
|
712
|
|
|
103
|
|
|
288
|
|
|
136
|
|
|
185
|
|
|||||
Purchase obligations
|
|
238
|
|
|
58
|
|
|
136
|
|
|
21
|
|
|
23
|
|
|||||
Merger consideration obligations
|
|
80
|
|
|
51
|
|
|
28
|
|
|
1
|
|
|
—
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total contractual obligations
|
|
$
|
6,653
|
|
|
$
|
295
|
|
|
$
|
969
|
|
|
$
|
724
|
|
|
$
|
4,665
|
|
ISSUER PURCHASES OF EQUITY SECURITIES
|
||||||||||||||
Period
|
|
Total Number of
Shares
Purchased
|
|
Average Price
Paid per Share
|
|
Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
|
|
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs
(in thousands)
|
||||||
April 1, 2015 – April 30, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Share Repurchase Program (A)
|
|
26,319
|
|
|
$
|
75.23
|
|
|
26,319
|
|
|
$
|
583,627
|
|
Employee Transactions (B)
|
|
401
|
|
|
$
|
76.18
|
|
|
N/A
|
|
|
N/A
|
|
|
May 1, 2015 – May 31, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Share Repurchase Program (A)
|
|
508,073
|
|
|
$
|
71.86
|
|
|
508,073
|
|
|
$
|
547,115
|
|
Employee Transactions (B)
|
|
10,756
|
|
|
$
|
72.83
|
|
|
N/A
|
|
|
N/A
|
|
|
June 1, 2015 – June 30, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Share Repurchase Program (A)
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
547,115
|
|
Employee Transactions (B)
|
|
28
|
|
|
$
|
73.79
|
|
|
N/A
|
|
|
N/A
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Share Repurchase Program (A)
|
|
534,392
|
|
|
$
|
72.03
|
|
|
534,392
|
|
|
$
|
547,115
|
|
Employee Transactions (B)
|
|
11,185
|
|
|
$
|
72.96
|
|
|
N/A
|
|
|
N/A
|
|
(A)
|
Since the share repurchase program’s inception in May 2003, our Board of Directors has authorized $6.5 billion of share repurchases of our common stock through
June 30, 2015
. The share repurchase authorization has no set expiration or termination date.
|
(B)
|
Includes: (1) shares delivered or attested to in satisfaction of the exercise price and/or tax withholding obligations by holders of stock options (granted under the Company’s Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan, collectively the “Stock Compensation Plans”) who exercised options; and (2) shares withheld (under the terms of grants under the Stock Compensation Plans) to offset tax withholding obligations that occur upon the delivery of common shares underlying restricted stock units and performance share units.
|
Item 6.
|
Exhibits
|
10.1
|
Amended and Restated Quest Diagnostics Incorporated Employee Long-Term Incentive Plan (As amended May 15, 2015)
|
|
|
10.2
|
Amended and Restated Employee Stock Purchase Plan (Effective as of June 29, 2015)
|
|
|
31.1
|
Rule 13a-14(a) Certification of Chief Executive Officer
|
|
|
31.2
|
Rule 13a-14(a) Certification of Chief Financial Officer
|
|
|
32.1
|
Section 1350 Certification of Chief Executive Officer
|
|
|
32.2
|
Section 1350 Certification of Chief Financial Officer
|
|
|
101.INS
|
dgx-20150630.xml
|
|
|
101.SCH
|
dgx-20150630.xsd
|
|
|
101.CAL
|
dgx-20150630_cal.xml
|
|
|
101.DEF
|
dgx-20150630_def.xml
|
|
|
101.LAB
|
dgx-20150630_lab.xml
|
|
|
101.PRE
|
dgx-20150630_pre.xml
|
|
|
|
|
By
|
/s/ Stephen H. Rusckowski
|
|
|
Stephen H. Rusckowski
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
By
|
/s/ Mark J. Guinan
|
|
|
Mark J. Guinan
|
|
|
Senior Vice President and Chief Financial Officer
|
|
1.
|
THE PLAN
|
2.
|
ADMINISTRATION
|
3.
|
SHARES SUBJECT TO THE PLAN AND ADJUSTMENTS
|
4.
|
TYPES OF AWARDS
|
5.
|
AWARD SETTLEMENTS AND PAYMENTS
|
6.
|
PLAN AMENDMENT AND TERMINATION
|
7.
|
CHANGE IN CONTROL
|
8.
|
MISCELLANEOUS
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Quest Diagnostics Incorporated;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a.
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
By
|
/s/ Stephen H. Rusckowski
|
|
|
|
Stephen H. Rusckowski
|
|
President and Chief Executive Officer
|
|
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Quest Diagnostics Incorporated;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c.
|
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a.
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b.
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
By
|
/s/ Mark J. Guinan
|
|
|
|
Mark J. Guinan
|
|
Senior Vice President and
|
|
Chief Financial Officer
|
Dated:
|
July 30, 2015
|
|
/s/ Stephen H. Rusckowski
|
|
|
|
|
|
|
|
|
|
Stephen H. Rusckowski
|
|
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
Dated:
|
July 30, 2015
|
|
/s/ Mark J. Guinan
|
|
|
|
|
|
|
|
|
|
Mark J. Guinan
|
|
|
|
|
Senior Vice President and
|
|
|
|
|
Chief Financial Officer
|
|